大洋生物(003017) - 2025 Q2 - 季度业绩预告

Zhejiang Dayang Bio-Tech Group Co., Ltd. 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company anticipates a year-on-year increase in its 2025 first-half performance, with net profit attributable to shareholders projected between RMB 45 million and RMB 55 million, representing a 43.15% to 74.96% growth, and non-recurring net profit between RMB 42 million and RMB 52 million, growing 44.38% to 78.75% Key Indicators of 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: RMB 45 million - RMB 55 million | Profit: RMB 31.4363 million | | Year-on-Year Change | Increase 43.15% - 74.96% | - | | Net Profit After Deducting Non-Recurring Gains and Losses | Profit: RMB 42 million - RMB 52 million | Profit: RMB 29.0902 million | | Year-on-Year Change | Increase 44.38% - 78.75% | - | | Basic Earnings Per Share | Profit: RMB 0.55/share - RMB 0.68/share | RMB 0.39/share | Explanation of Performance Changes The significant performance growth in the current period is primarily driven by core products, with increased production and sales volumes of potassium carbonate and veterinary APIs, coupled with favorable market supply-demand dynamics leading to higher product prices and improved gross margins - Performance growth is primarily attributed to increased production and sales volumes of the company's main products, potassium carbonate and veterinary APIs, along with price increases driven by changes in market supply and demand, ultimately leading to an improved gross margin[4] Other Important Information The financial data in this performance forecast represents preliminary estimates by the company's finance department and has not been audited by an accounting firm, with investors advised to refer to the final 2025 semi-annual report for specific figures and exercise caution regarding investment risks - The financial data in this performance forecast has not been pre-audited by Zhonghui Certified Public Accountants (Special General Partnership)[3] - This performance forecast is a preliminary estimate by the company's finance department, and the final data will be subject to the 2025 semi-annual report to be disclosed by the company, urging investors to make prudent decisions[5]